The U.S. Food and Drug Administration (FDA) has accepted an application from Uganda’s Dei BioPharma for the review of its Abbreviated New Drug Application (ANDA) for liraglutide, a multibillion-dollar treatment...
Learn how Contract Development and Manufacturing Organizations(CDMOs) like Dei Biopharma are transforming pharmaceutical manufacturing in Uganda and across Africa.
UGANDA—Dr. Matthias Magoola, the founder and Managing Director of Dei Biopharma Ltd, has been honoured as a distinguished recipient of the African Excellence & Personality Awards 2025.
Abstract: MicroRNAs (miRNAs) maintain cellular homeostasis by blocking mRNAs by binding with them to fine-tune the expression of genes across numerous biological pathways.
Dr. Matthias Magoola Recognized at International Molecular Biologist Awards for Vaccine Research KAMPALA – Recognition for Groundbreaking Work in mRNA and Therapeutic Proteins Dr. Matthias Magoola, Founder and Managing Director...
MPs Urge Dei Biopharma to Accelerate Production of Life-Saving Medicines KAMPALA, September 29, 2024 – Members of Parliament on the Health Committee have urged Dei Biopharma Vaccines Manufacturing Plant to...
